Join the Oncology Voice Network. Join for Free
TEXT: Mapping Customer Journeys in a Digital World
Key Opinion Leaders Digital Communication Medical Science Liaison Social Media Engagement Compassionate Leadership

TEXT: Mapping Customer Journeys in a Digital World


Share This Article


Summary

In this episode, Tom Caravela is joined by Mitchell D’Rozario to explore the challenges and strategies in engaging with Key Opinion Leaders (KOLs). They discuss the importance of understanding digital communication preferences and establishing value through effective timing and methods. The conversation delves into leveraging publication history and digital tools to enhance MSL access and engagement, while balancing virtual and in-person interactions. They highlight the role of compassionate leadership, navigating social media, and adapting strategies in difficult times. Mitchell shares insights on overcoming obstacles, learning from failures, and provides tips for aspiring MSLs.

Mitchell D’Rozario, Medical Science Liaison at Genentech discusses digital tools and techniques for MSLs to Map Customer Journeys: pain points and opportunities.

Mitch shares…

👉 How to go about developing a TEXT relationship with your Key Opinion Leaders

👉 What key questions you should be asking

👉 How and why the use of social media is so important

👉 Unique ways to engage with KOLs and gain better access

👉 Advice on performance and meeting goals

Click for Source
Key Opinion Leaders, Digital Communication, Medical Science Liaison, Social Media Engagement, Compassionate Leadership

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates

Explore OVN